Close

BioLineRx (BLRX) Presents Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/16/2024

1. GS
2. JNJ
3. UNH
4. SPY
5. MSFT
6. BK
7. TSLA
8. BAC
9. MBWM
10. SCHW


Go back to BioLineRx (BLRX) Presents Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization
BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 0.64 --0 (-0%)
Previous Close $0.64    52 Week High $1.63 
Open $0.64    52 Week Low $0.71 
Day High $0.64    P/E N/A 
Day Low $0.64    EPS $0.00 
Volume 450